| Identification | Back Directory | [Name]
SAR-020106 | [CAS]
1184843-57-9 | [Synonyms]
SAR20106
SAR 20106
SAR-020106
SAR-020106 >=95%
SAR020106; SAR020106; SAR 020106; SAR20106; SAR20106; SAR 20106
(R)-5-((8-chloroisoquinolin-3-yl)amino)-3-((1-(dimethylamino)propan-2-yl)oxy)pyrazine-2-carbonitrile
5-[(8-Chloro-3-isoquinolinyl)amino]-3-[(1R)-2-(dimethylamino)-1-methylethoxy]-2-pyrazinecarbonitrile
2-Pyrazinecarbonitrile, 5-[(8-chloro-3-isoquinolinyl)amino]-3-[(1R)-2-(dimethylamino)-1-methylethoxy]- | [Molecular Formula]
C19H19ClN6O | [MDL Number]
MFCD28155090 | [MOL File]
1184843-57-9.mol | [Molecular Weight]
382.85 |
| Hazard Information | Back Directory | [Uses]
5-[(8-Chloro-3-isoquinolinyl)amino]-3-[(1R)-2-(dimethylamino)-1-methylethoxy]-2-pyrazinecarbonitrile is a potent and selective CHK1 inhibitor. CHK1 is a serine/threonine kinase involved with DNA damage repair and cell cycle arrest. | [in vivo]
SAR-020106 (40 mg/kg; i.p.; administered on days 0, 1, 7, 8, 14, and 15) in combination with Irinotecan potentiates the antitumor activity in SW620 xenografts[1]. | Animal Model: | Nude mice bearing SW620 xenograft tumors[1] | | Dosage: | 40 mg/kg | | Administration: | I.p.; administered on days 0, 1, 7, 8, 14, and 15 | | Result: | There was a clear decrease in tumor growth associated with the combination with tumors reaching 300% by 12.5 days.
|
| [IC 50]
Chk1: 13.3 nM (IC50) |
|
| Company Name: |
Twochem Co.Ltd
|
| Tel: |
021-021-58111628 15800915896 |
| Website: |
www.twochem.com |
|